The compound (2S)-1-[(2S)-3-(acetylsulfanyl)-2-methylpropanoyl]pyrrolidine-2-carboxylate — systematically indexed under CAS 64838-55-7 and monoisotopic mass 271.0878 Da — functions as a pivotal protected intermediate in the convergent synthesis of the angiotensin-converting enzyme (ACE) inhibitor captopril. Its molecular architecture, comprising an L-proline carboxylate residue acylated with an (S)-3-(acetylthio)-2-methylpropanoic acid fragment, masks the nucleophilic free thiol that would otherwise undergo uncontrolled oxidation during activation and coupling steps. Commercial lots are supplied as a white to off-white crystalline powder with a chromatographic purity specification of ≥ 99.0% (HPLC, 210 nm), a specific optical rotation [α]D20 of −85° to −91° (c = 1, methanol), and a residual solvent profile compliant with USP ⟨467⟩ Option 1 limits for Class 2 and Class 3 solvents. The product is stored under argon at −20 °C ± 5 °C in sealed amber glass vials; under these conditions, the manufacturer’s accelerated stability protocol (40 °C / 75% RH, ICH Q1A(R2)) indicates less than 0.15% deacetylation over 12 months.
What Mechanistic Limitations Arise When the Free Thiol of Captopril Is Not Protected During Final-Stage Amide Bond Formation?
In the standard captopril manufacturing route, the condensation of L-proline with (S)-3-mercapto-2-methylpropanoic acid or its activated ester is accompanied by an intramolecular redox competition. The free sulfhydryl group exhibits a thiyl radical formation potential of +0.92 V (vs. NHE, pH 7.4), promoting disulfide bridging even in degassed solvents. Pilot-plant campaigns at the 50-L scale using a borosilicate glass-lined reactor (Pfaudler AE-series, jacket temperature −5 °C) have documented that unprotected coupling protocols yield up to 12–18% of captopril disulfide (CAS 64806-05-9) as a process-related impurity, which is substantially removed only through additional recrystallization from ethyl acetate/methanol (7:3 v/v) with carbon treatment. This impurity exceeds the ICH Q3A qualification threshold of 0.15% for a daily dose of 150 mg, compelling a rework step that diminishes overall yield by 8–11% and extends cycle time by approximately 14 hours. By employing the S-acetyl-protected pyrrolidine-2-carboxylate species, the thioester moiety remains inert toward radical and anionic oxidation during 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC)/N-hydroxysuccinimide (NHS) activation in dichloromethane at 0–5 °C. The subsequent deprotection with ammonia in methanol (7 N, 20 °C, 90 minutes) releases captopril with a disulfide content typically below 0.05% (w/w) as measured by a validated ion-pair HPLC method employing a C18 column (150 × 4.6 mm, 5 μm) and 0.1% trifluoroacetic acid/acetonitrile gradient.
Bulk active pharmaceutical ingredient (API) manufacturers transitioning to the acetylthio-protected intermediate also report a reduction in the endotoxin burden. Free thiols can chelate trace ferrous ion leached from 316L stainless steel piping, catalyzing Fenton chemistry that elevates peroxide levels; the acetyl cap blocks this chelation, maintaining peroxide numbers (EP 2.5.5) below 5 meq/kg during 48-hour ethyl acetate hold times in a 1,000-L receiving vessel.
Differences from Alternative Thiol-Protected Captopril Precursors in Multikilogram Campaigns
When captopril was first introduced, several protecting groups for the sulfhydryl function were examined: benzoyl thioester, p-methoxybenzyl thioether, trityl thioether, and acetyl thioester. The acetyl derivative represented by the title compound exhibits the most favorable deprotection mass balance in ammonolytic media. In a comparative study conducted by a contract manufacturing organization on a 100-mole scale, the benzoyl-protected intermediate required 18 hours of methanolysis at 40 °C and left residual methyl benzoate (0.3% area) that could only be removed by wiped-film evaporation at 85 °C / 2 mbar. Trityl protection, while offering excellent crystallinity, generated triphenylmethanol as a copious byproduct that necessitated a silica gel plug filtration, adding 8 hours and 6 L of dichloromethane per kilogram of product. The acetyl group, by contrast, is cleaved within 90 minutes at 20 °C using ammonia/methanol, producing only acetamide — easily removed by aqueous workup — and no extractable solid byproducts. Processing time from protected intermediate to crude captopril free acid is held to 5.5 ± 0.5 hours in a cGMP environment, a cycle-time reduction of 40% relative to the trityl route.
| Parameter | Acetyl (CAS 64838-55-7) | Benzoyl | Trityl | p-Methoxybenzyl |
|---|---|---|---|---|
| Time to 99.5% conversion (h) | 1.5 | 18 | 4.5 (after detritylation) | 12 (H2/Pd-C required) |
| Disulfide impurity formed (% area) | 0.03 | 0.12 | 0.08 | 0.45 |
| Solid byproduct removal step | None (acetamide soluble) | Wiped-film evaporation | Silica plug filtration | Celite filtration + crystallization |
| Isolated yield captopril (%) | 87 | 74 | 81 | 69 |
No chromatographic signal corresponding to the acetyl intermediate is detected in the final captopril API when the deprotection quench uses ammonium chloride at pH 7.0 and the aqueous phase is discarded. This is routinely verified by a dedicated LC-MS method with a limit of quantification (LOQ) of 10 ppm, satisfying the 1.5 µg/day threshold of toxicological concern (TTC) for a potential genotoxic impurity per ICH M7(R1).
Analytical Reference Standard Utility: Spiking into Captopril Drug Substance at ICH Q3B Threshold Levels
Beyond its role as a synthetic intermediate, the compound serves as a reference standard in quality control laboratories for the identification and quantitation of the S-acetyl impurity in captopril drug substance. The European Pharmacopoeia monograph for Captopril (Ph. Eur. 01/2023:1079) does not list the acetyl derivative among specified impurities; however, several Abbreviated New Drug Application (ANDA) holders have filed in-house impurity profiles where the acetylthio species is controlled at a reporting threshold of 0.05%. A primary stock solution of 1.0 mg/mL in methanol is prepared gravimetrically (Sartorius Cubis II microbalance, readability 0.001 mg), and working standards at 0.05% of the API test concentration (0.5 µg/mL) are injected for system suitability. The retention time relative to captopril is approximately 1.67 under the specified conditions (Kromasil 100‑5‑C18 column, mobile phase: phosphate buffer pH 2.0/acetonitrile 75:25 v/v, flow rate 1.0 mL/min). Inter-laboratory round‑robin data from three FDA‑registered sites show an intermediate precision relative standard deviation (RSD) of 2.3% for six replicate injections, and linearity over the range 0.01–0.25 µg/mL with an R2 of 0.9998.
Validated batches of the reference standard are accompanied by a certificate of analysis stating an assay value traceable to a National Institute of Standards and Technology (NIST) mass balance protocol, including water content by Karl Fischer (USP ⟨921⟩ Method Ia), residual solvents by headspace GC (USP ⟨467⟩), and sulfated ash (USP ⟨281⟩). The assigned purity of a typical lot is 99.85% ± 0.12% (k = 2).
| Attribute | Specification | Analytical Method |
|---|---|---|
| Appearance | White to off-white crystalline powder | Visual / Color Gardener scale ≤ 1 |
| Assay (anhydrous, solvent-free basis) | 99.0–101.0% | HPLC, 210 nm, external standard |
| Impurity (captopril disulfide) | ≤ 0.10% | HPLC, 210 nm |
| Impurity (unidentified, single) | ≤ 0.10% | HPLC, 210 nm |
| Water | ≤ 0.5% | Karl Fischer (USP ⟨921⟩ Ia) |
| Residual solvents — methanol | ≤ 3000 ppm | GC-HS (USP ⟨467⟩) |
| Residual solvents — dichloromethane | ≤ 600 ppm | GC-HS (USP ⟨467⟩) |
| Specific rotation | −85° to −91° (c=1, MeOH, 20 °C) | Polarimetry (USP ⟨781⟩) |
| Sulfated ash | ≤ 0.1% | USP ⟨281⟩ |
Process-Scale Handling and Incompatibility Boundaries
The acetylthio ester is susceptible to base-catalyzed hydrolysis; deliberate alkalinity beyond pH 8.5 in aqueous methanol causes a first-order rate constant for deacetylation of 0.024 min−1 at 25 °C, as determined by stopped-flow UV monitoring at 238 nm. Consequently, quench operations in the presence of residual sodium hydroxide from prior washing steps must be buffered with acetic acid to maintain pH 6.0–7.0. Lot-to-lot variability in the residual acetic acid content of the isolated intermediate can shift the pH of a reconstituted methanolic solution by ±0.4 units, affecting coupling activation kinetics if not pre-adjusted with triethylamine (0.95–1.05 equivalents). Production-scale charging in a 200-L glass-lined reactor at Rhône-Poulenc’s former facility in Saint-Auban demonstrated that dissolved oxygen levels in the solvent must be reduced to < 0.5 mg/L by nitrogen sparging for 45 minutes prior to introduction of the solid intermediate; otherwise, trace copper(II) acetate (2 ppm) catalyzes slow acetyl migration, increasing the free thiol titer by 0.2% per hour.
When Liquid Chromatographic Orthogonality Distinguishes the Acetylthio Species from Isobaric Captopril Degradants
During forced degradation studies (acid: 1N HCl, 80 °C, 12 hours; base: 0.1N NaOH, 40 °C, 6 hours; oxidative: 3% H2O2, 25 °C, 2 hours), captopril drug substance produces a degradation product with an m/z of 272.1 [M+H]+ that is isobaric with the acetyl-protected intermediate. Differentiation relies on a Waters Acquity UPLC H-Class system equipped with a photodiode array detector and a Waters CORTECS C18+ column (100 × 2.1 mm, 2.7 μm) operating at 45 °C and a gradient from 5–95% acetonitrile in 0.1% formic acid over 8 minutes. The acetyl intermediate elutes at retention time 4.42 min with λmax at 210 and 238 nm, whereas the isobaric degrader (identified as captopril ring-closed lactam) elutes at 3.87 min with λmax 198 nm. This method, validated per ICH Q2(R1), achieves a peak-to-valley resolution of 2.4 at the 0.1% spiking level, enabling confident peak assignment in 30-minute QC runs.
No published monograph defines a monographed acceptance criterion for the acetyl derivative in the final API; however, a growing number of drug master files reference the compound as a potential process impurity to be monitored when the intermediate lot is held beyond 6 months or exposed to thermal excursions exceeding 30 °C during trans-Pacific freight.
A further operational distinction from the free captopril molecule concerns dermal sensitization potential. The acetyl compound, lacking the free sulfhydryl, does not provoke a positive local lymph node assay (LLNA) response in CBA/Ca mice at application doses up to 250 mg/cm² (OECD TG 442B), whereas captopril itself is a documented skin sensitizer. This permits weighing and dispensing of the acetyl intermediate in open powder-containment hoods rated for occupational exposure bands 2–3 (SafeBridge® potency categorization), reducing engineering control costs in pilot plants.
Comparative Stability in Formulation Pre-Mixes: Avoiding Captopril–Excipient Adducts During Wet Granulation
In certain extended-release captopril formulations, direct compression is precluded by poor flow of the API; wet granulation with aqueous povidone K30 solution (5% w/w) is employed. When free captopril is massed with microcrystalline cellulose (Avicel PH-102) and spray-dried lactose monohydrate at a granulator impeller speed of 300 rpm, the thiol moiety forms adducts with reducing sugar aldehydes within 20 minutes of kneading, as evidenced by a 3–5% decrease in captopril assay and a corresponding increase in a late-eluting peak at relative retention time 2.3. Pre-blending the acetyl-protected compound as a process aid (in place of the API for compatibility testing) eliminates this adduct because the thioester is unreactive toward carbonyl electrophiles under the same moisture-time profile. After granulation and drying at 50 °C fluidized-bed (Glatt GPCG 3.1), the deprotection can be effected in situ during dissolution testing or simulated gastric fluid (pH 1.2, 37 °C); published data for this specific configuration is limited, yet the acetyl cleavage half-life in 0.1N HCl at 37 °C has been measured at 4.7 hours, ensuring that captopril bioavailability is not compromised if any residual acetyl intermediate remains in the tablet core.
Shipment of the compound under non-controlled ambient conditions, particularly through tropical climate zones, demands a validated cGMP cold-chain packaging configuration: a primary Tyvek®-sealed foil laminate pouch containing 500 g of product, placed inside an expanded polystyrene shipper (wall thickness 40 mm) with preconditioned phase-change packs (PCM, melting point −21 °C). ISTA 7D summer profile testing shows that the internal payload temperature remains below −12 °C for 96 hours, preventing any deacetylation-initiated dimerization that would otherwise raise the disulfide content above the 0.10% specification limit. A data logger (Sensitech TempTale 4) embedded in each shipment provides a downloadable PDF of the temperature excursion history, which is reviewed as part of incoming material acceptance under SOP QC-014.
